| NCT ID | NCT07333612 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Condition | Cystic Echinococcosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-09-23 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-09-23 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Comparison of immunoblotting bands pattern in patients with treated versus untreated echinococcal cysts of the liver
Eligibility Criteria
Inclusion Criteria: * Only Hepatic echinococcal cysts * Age \> 18 years * At leat 2 clinical evaluation Exclusion Criteria: * different location of echinococcal cysts * Age \< 18 years --less then 2 clinical evalutation
Frequently Asked Questions
Who can join the NCT07333612 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cystic Echinococcosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07333612 currently recruiting?
Yes, NCT07333612 is actively recruiting participants. Visit ClinicalTrials.gov or contact Fondazione IRCCS Policlinico San Matteo di Pavia to inquire about joining.
Where is the NCT07333612 trial being conducted?
This trial is being conducted at Pavia, Italy.
Who is sponsoring the NCT07333612 clinical trial?
NCT07333612 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. The trial plans to enroll 100 participants.